OSE Immunotherapeutics SA
PAR:OSE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
OSE Immunotherapeutics SA
Cash & Cash Equivalents
OSE Immunotherapeutics SA
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
OSE Immunotherapeutics SA
PAR:OSE
|
Cash & Cash Equivalents
€25.4m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
2%
|
CAGR 10-Years
3%
|
|
|
Valneva SE
PAR:VLA
|
Cash & Cash Equivalents
€109.7m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
10%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Cash & Cash Equivalents
€101.1m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
5%
|
|
|
Inventiva SA
PAR:IVA
|
Cash & Cash Equivalents
€99.3m
|
CAGR 3-Years
5%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Cash & Cash Equivalents
$194.2m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-5%
|
|
|
Abivax SA
PAR:ABVX
|
Cash & Cash Equivalents
€516.7m
|
CAGR 3-Years
168%
|
CAGR 5-Years
78%
|
CAGR 10-Years
N/A
|
|
OSE Immunotherapeutics SA
Glance View
OSE Immunotherapeutics SA develops immunotherapy products for cancer and auto-immune disease. The company is headquartered in Nantes, Pays De La Loire and currently employs 61 full-time employees. The company went IPO on 2015-03-30. The company develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The firm's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. The company provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.
See Also
What is OSE Immunotherapeutics SA's Cash & Cash Equivalents?
Cash & Cash Equivalents
25.4m
EUR
Based on the financial report for Jun 30, 2025, OSE Immunotherapeutics SA's Cash & Cash Equivalents amounts to 25.4m EUR.
What is OSE Immunotherapeutics SA's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
3%
Over the last year, the Cash & Cash Equivalents growth was -2%. The average annual Cash & Cash Equivalents growth rates for OSE Immunotherapeutics SA have been -7% over the past three years , 2% over the past five years , and 3% over the past ten years .
